Active, not recruitingPhase 1NCT04041050
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Navitoclax(drug)
- Enrollment
- 85 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- City of Hope /ID# 239769, Duarte, California, United States
- Providence - St. Jude Medical Center /ID# 242558, Fullerton, California, United States
- Moores Cancer Center at UC San Diego /ID# 229584, La Jolla, California, United States
- UCLA /Id# 222784, Los Angeles, California, United States
- Northwestern University Feinberg School of Medicine /ID# 224203, Chicago, Illinois, United States
- Norton Cancer Institute - St. Matthews /ID# 239300, Louisville, Kentucky, United States
- Duplicate_Brigitte Harris Cancer Pavilion /ID# 238686, Detroit, Michigan, United States
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 242554, Omaha, Nebraska, United States
- Duplicate_East Carolina University Brody School of Medicine /ID# 238560, Greenville, North Carolina, United States
- Gabrail Cancer Center Research /ID# 228924, Canton, Ohio, United States
- Pennsylvania Cancer Specialists Research Institute - Gettysburg /ID# 242550, Gettysburg, Pennsylvania, United States
- Virginia Commonwealth University Medical Center Main Hospital /ID# 228169, Richmond, Virginia, United States
- Cliniques Universitaires UCL Saint-Luc /ID# 225314, Woluwe-Saint-Lambert, Brussels Capital, Belgium
- UMHAT Sveti Georgi /ID# 240022, Plovdiv, Bulgaria
- UMHAT Sveti Ivan Rilski /ID# 240077, Sofia, Bulgaria
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04041050 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGNANCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)University Hospital, Bordeaux
- RECRUITINGPHASE2NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami
- RECRUITINGNCT06480591Evaluation of the Pathobiology of CALR-mutated MPN CellsWake Forest University Health Sciences